Celltrion's treatment for chronic idiopathic urticaria and allergic asthma, OMLYCLO (ingredient name Omalizumab), is rapidly increasing its market share as tenders and prescriptions expand in major European countries.
According to Celltrion on the 13th, OMLYCLO is continuing to post tender wins and expand prescriptions in major European countries, including Italy, the United Kingdom, and Germany. OMLYCLO is the first biosimilar of XOLAIR, an antibody therapy co-developed by U.S.-based Novartis and Switzerland-based Roche.
In Italy, the company won bids in 10 out of a total of 14 State Governments-level tenders and began supplying. The company plans to expand results in the remaining regional tenders and build a nationwide supply network.
In the United Kingdom, it secured supply rights across all four administrative regions, including England, through a National Health Service (NHS) tender. As it had already posted a double-digit share before the official tender, prescriptions are expected to increase as supply expands.
Germany is also seeing rapid early traction. Launched in September last year, OMLYCLO reached a double-digit market share within a month of sales and has maintained its growth since. Right after launch, it completed listing contracts with major statutory health insurers, and marketing leveraging existing sales networks has translated into results.
In Northern Europe, tender-based results stand out. In Denmark, after launching four months earlier than initially planned, it secured exclusive supply status and posted a 98% share as of January this year. In Finland, it secured a 73% share as of February, indicating a rapid switch from the original product to the biosimilar.
Spain and the Netherlands are also seeing continued share gains. In Spain, it was selected as the first-priority supplier in tenders at public medical institutions in key regions such as Catalonia and the Basque Country, posting about an 80% share. In the Netherlands, it secured more than a 70% share through hospital group tenders.
Celltrion cited product competitiveness, stable supply, and field-centered sales and marketing as key performance drivers. It plans to sequentially launch a 300 mg formulation in major European countries to strengthen competitiveness and further expand prescriptions.
Ha Tae-hoon, head of Celltrion's Europe division, said, "Initial results are being confirmed as tenders and prescription expansion proceed simultaneously across European countries," adding, "We will foster OMLYCLO as a new growth pillar by expanding sales territories."